New Frontiers in
Thrombosis Reduction
for Heart Disease

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period August 31, 2011 through August 31, 2012, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Estimated Time to Complete Educational Activity:

2.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of and strategies for preventing thrombosis in the setting of acute coronary syndrome and atrial fibrillation.

Release Date:

August 31, 2010

Expiration Date:

August 31, 2012

Intended Audience:

• Cardiologists
• Preventive cardiologists
• Cardiovascular electrophysiologists
• Neurovascular specialists
• Vascular medicine specialists
• Anticoagulation experts
• Heart failure specialists
• Coronary care unit (CCU) specialists and directors
• Program directors, cardiovascular medicine
• Fellows in cardiovascular medicine
• Clinical pharmacists and pharmacologists
• Pharmacy directors (cardiovascular medicine)
• Investigators and clinical trial specialists
• Cardiovascular nurses

Registration:

Enrollment for this WebCAST WRAP is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Jointly sponsored by Postgraduate Institute for Medicine and CMEducation. www.pimed.com

Supported by an independent
educational grant from the
Bristol-Myers Squibb/Pfizer Partnership

Physician Continuing Education:

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and CMEducation Resrouces. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Program Faculty and Disclosures:

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI – Program Chairman
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women’s Hospital and the VA Boston Healthcare System
Senior Investigator, TIMI Group
Harvard Medical School
Boston, MA

Consultant: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Takeda, The Medicines Company, Vertex.
Principal Investigator for several potentially related studies. His institution has received funding from Bristol Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company.


Shamir Mehta, MD, MSc, FACC, FRCPC
Director, Interventional Cardiology
Hamilton Health Sciences
Associate Professor
McMaster University
Hamilton, Ontario, Canada

Grant/Research Support: Bristol-Myers Squibb Company, GlaxoSmithKline, sanofi-aventis
Consultant: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc, sanofi-aventis
Honorarium: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc, Sanofi-Aventis


Gregory Y.H. Lip, MD,FRCP, FACC, FESC
Consultant Cardiologist and Professor of Cardiovascular Medicine
Director, Haemostasis Thrombosis & Vascular Biology Unit
University of Birmingham Centre for Cardiovascular Sciences
City Hospital
Birmingham, England

Research support: sanofi-aventis, Bayer HealthCare Pharmaceuticals.
Advisor or consultant: Astellas Pharma, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, AstraZeneca Pharmaceuticals LP, and sanofi-aventis.


David A. Garcia, MD
Associate Professor, Division of General Internal Medicine
University of New Mexico
Co-Director, University of New Mexico Anticoagulation Management Service
President, Anticoagulation Forum
Albuquerque, New Mexico USA

Advisor or consultant for: Bohringer Ingelhim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, ARYx Therapeutics, CSL Behring.
Received grants for clinical research from: Bristol-Myers Squibb Company, ARYx Therapeutics, CSL Behring


Richard C. Becker, MD
Professor of Medicine
School of Medicine
Duke University
Director, Duke Cardiovascular Thrombosis Center
Duke Clinical Research Institute
Durham, North Carolina USA

Grant/Research Support: Johnson & Johnson, Bristol-Myers Squibb, Bayer, Merck, Regado Biosciences

Program Managers and Web Editor Disclosure:

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months..

Educational Objectives:

Participants in this CME-certified WebCAST will:

• Discuss advances in oral anticoagulation based on new mechanisms involving inhibition of the coagulation cascade
• Discuss advances in oral anticoagulation based on new mechanisms involving inhibition of the coagulation cascade and possible implications for thrombosis risk reduction across the CV disease morbidity continuum.
• Outline the safety and efficacy of such established therapies as warfarin on patients at risk for stroke in the setting of AF
• Describe how to risk stratify patients for incurring stroke in the setting of AF
• Summarize current and evolving prophylaxis measures that can reduce the incidence of stroke.
• Explain current ACC/AHA, ACCP, and AAN guidelines for stroke prevention in the setting of AF.
• List novel, evidence-based approaches for residual risk reduction and secondary prevention of adverse thromboembolic events in a broad range of patients with heart disease
• Apply results from clinical trials focusing on thromboembolic risk prevention in patients with ACS and atrial fibrillation.
  

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.
  

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), CMEducation Resources and Eisai, Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CMEducation Resources and Eisai, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Copyright © 2011 Resources, LLC All rights reserved.